title: Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen.
abstract: BACKGROUND
  Pharmacogenetic study of cytochrome P450 (CYP) gene CYP2D6 and tamoxifen outcomes remain controversial. Apart from CYP2D6, other drug-metabolizing enzymes and transporters also play a role in tamoxifen metabolic pathways. The aim of this study is to investigate the impact of CYP3A4/5, ABCB1, and ABCC2 polymorphisms on the risk of recurrence in Thai patients who received tamoxifen adjuvant therapy.
  
  
  METHODS
  Patients with early-stage breast cancer who received tamoxifen adjuvant therapy were recruited in this study. All six single-nucleotide polymorphisms (SNPs), including CYP3A4*1B (-392 A>G)/*18(878 T>C), CYP3A5*3(6986 G>A), ABCB1 3435 C>T, ABCC2*1C(-24 C>T), and ABCC2 68231 A>G, were genotyped using real-time polymerase chain reaction assays. The impacts of genetic variants on disease-free survival (DFS) were analyzed using the Kaplan-Meier method and Cox regression analysis.
  
  
  RESULTS
  The ABCB1 3435 C>T was found to have the highest allele frequency among other variants; however, CYP3A4*1B/*18 could not be found in this study. Patients with heterozygous ABCB1 3435 CT genotype showed significantly shorter DFS than those with homozygous 3435 CC genotype (P = 0.041). In contrast, patients who carried homozygous 3435 TT genotype showed no difference in DFS from wild-type 3435 CC patients. Cox regression analysis showed that the relative risk of recurrence was increased by five times (P = 0.043; hazard ratio = 5.11; 95% confidence interval: 1.05-24.74) in those patients carrying ABCB1 3435 CT genotype compared to those with ABCB1 3435 CC.
  
  
  CONCLUSIONS
  ABCB1 3435 C>T is likely to have a clinically significant impact on recurrence risk in Thai patients with breast cancer who receive tamoxifen adjuvant therapy.
authors.affiliation: Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand.
authors.forename: Insee
authors.initials: I
authors.lastname: Sensorn
authors.forename: Ekaphop
authors.initials: E
authors.lastname: Sirachainan
authors.forename: Montri
authors.initials: M
authors.lastname: Chamnanphon
authors.forename: Ekawat
authors.initials: E
authors.lastname: Pasomsub
authors.forename: Narumol
authors.initials: N
authors.lastname: Trachu
authors.forename: Porntip
authors.initials: P
authors.lastname: Supavilai
authors.forename: Chonlaphat
authors.initials: C
authors.lastname: Sukasem
authors.forename: Darawan
authors.initials: D
authors.lastname: Pinthong
keywords: CYP3A4/5; breast cancer; disease-free survival; drug transporters; pharmacogenetics; tamoxifen
references.citation: Cancer Res. 2002 Sep 1;62(17):4955-62
references.pmid: 12208746
references.citation: Ann Hepatol. 2012 Nov-Dec;11(6):899-906
references.pmid: 23109454
references.citation: Clin Cancer Res. 2010 Sep 1;16(17):4468-77
references.pmid: 20515869
references.citation: Pharmacogenomics J. 2007 Feb;7(1):56-65
references.pmid: 16788565
references.citation: Pharmacogenomics J. 2011 Feb;11(1):25-34
references.pmid: 20351751
references.citation: Int J Mol Epidemiol Genet. 2013;4(1):35-48
references.pmid: 23565321
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5187-93
references.pmid: 18024866
references.citation: Jpn J Clin Oncol. 2009 Oct;39(10):651-6
references.pmid: 19596663
references.citation: J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75
references.pmid: 15159443
references.citation: Curr Cancer Drug Targets. 2004 May;4(3):257-65
references.pmid: 15134533
references.citation: Asian Pac J Cancer Prev. 2012;13(9):4549-53
references.pmid: 23167378
references.citation: Nat Rev Cancer. 2009 Aug;9(8):576-86
references.pmid: 19629072
references.citation: J Natl Cancer Inst. 2012 Mar 21;104(6):441-51
references.pmid: 22395644
references.citation: Ann Oncol. 2009 Feb;20(2):272-7
references.pmid: 18836089
references.citation: Cancer Lett. 2005 Jan 10;217(1):61-72
references.pmid: 15596297
references.citation: Clin Pharmacol Ther. 2011 May;89(5):718-25
references.pmid: 21430657
references.citation: J Pharmacol Exp Ther. 2011 Jun;337(3):710-7
references.pmid: 21378205
references.citation: Int J Oncol. 2003 May;22(5):1117-21
references.pmid: 12684679
references.citation: Ann Oncol. 2008 Aug;19(8):1423-1429
references.pmid: 18407954
references.citation: Science. 2007 Jan 26;315(5811):525-8
references.pmid: 17185560
references.citation: J Pharmacol Exp Ther. 2001 Dec;299(3):825-31
references.pmid: 11714865
references.citation: Clin Pharmacol Ther. 2011 May;89(5):708-17
references.pmid: 21451508
references.citation: Histopathology. 2010 Aug;57(2):202-11
references.pmid: 20716162
references.citation: Drug Metab Dispos. 1993 Jul-Aug;21(4):645-56
references.pmid: 8104124
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: Cancer. 2009 Mar 1;115(5):952-61
references.pmid: 19156902
references.citation: Br J Clin Pharmacol. 2011 May;71(5):737-50
references.pmid: 21480951
references.citation: J Hum Genet. 2011 Jun;56(6):415-22
references.pmid: 21412247
references.citation: Clin Pharmacol Ther. 2003 Sep;74(3):245-54
references.pmid: 12966368
references.citation: J Clin Oncol. 2010 Mar 10;28(8):1287-93
references.pmid: 20124171
references.citation: Clin Cancer Res. 2011 Nov 1;17(21):6944-51
references.pmid: 21880792
references.citation: J Korean Med Sci. 2011 Aug;26(8):1007-13
references.pmid: 21860550
references.citation: Pharmacogenetics. 2001 Dec;11(9):773-9
references.pmid: 11740341
references.citation: J Natl Cancer Inst. 2012 Mar 21;104(6):452-60
references.pmid: 22395643
references.citation: J Natl Cancer Inst. 2005 Jan 5;97(1):30-9
references.pmid: 15632378
references.citation: Endocr Relat Cancer. 2007 Jun;14(2):293-303
references.pmid: 17639045
references.citation: Drug Metab Dispos. 2012 Feb;40(2):389-96
references.pmid: 22096084
references.citation: BMC Cancer. 2010 Jun 21;10:313
references.pmid: 20565970
references.citation: Pharmacogenet Genomics. 2007 Jun;17(6):403-15
references.pmid: 17502832
references.citation: J Clin Oncol. 2005 Dec 20;23(36):9312-8
references.pmid: 16361630
references.citation: Pharmgenomics Pers Med. 2013 May 24;6:37-48
references.pmid: 23776391